

# Commercial Drug Formulation Technologies

Markets & Opportunities

February 2008



Greystone Associates  
98 Route 101A, Suite 17  
Amherst, NH 03031  
603-595-4340 • fax 603-804-0466

**The increasingly rapid introduction of therapeutically active biologics and bioengineered macromolecules is driving investment and interest in drug formulation technology**

**New formulation capabilities will expand the number of new NCEs that can be formulated to meet pharmacochemical thresholds**

**Advances in particle engineering, encapsulation, surface property optimization and solubility enhancement are enabling the creation of new formulations of both new and existing compounds**

**The new generation of formulations based on proprietary technology will present challenges to downstream pharmaceutical functions**

Greystone Associates is pleased to announce the publication of a new market study. **Commercial Drug Formulation Technologies** is a comprehensive evaluation and analysis of this rapidly advancing field of enabling technology, and its potential impact on drug development, formulation and compliance strategies across the pharmaceutical industry.

Published in February (2008), the study is designed to provide pharmaceutical companies, drug developers, formulators, assurance and compliance professionals, regulators and strategists with a detailed understanding of the methodologies, technologies, and industry impact presented by the wide range of drug formulation technologies and proprietary processes currently available or under development. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

#### **The Growing Impact of Proprietary Formulation Technologies**

As the pharmaceutical industry attempts to improve productivity and lower the business risks associated with new drug candidates, drug developers are increasingly turning to a generation of new, often proprietary, formulation technologies. These technologies can enhance key properties such as compound solubility or bioavailability - salvaging promising NCEs that would otherwise be dropped - and modulate release profiles to achieve dosage forms that enhance patient compliance.

While their potential is obvious, their use can result in complexities that can percolate throughout the organization. This impact extends beyond potential future drug therapeutics by bestowing valuable capabilities on formulators attempting to re-formulate approved drugs approaching the end of their patent life. As large-molecule therapeutics increase both in number and as a percentage of all drug discoveries, the appeal of drug formulation technologies will escalate. The survey covers twenty proprietary formulation technologies and processes, analyzing their potential challenges and opportunities.

# Table of Contents

## **Executive Summary**

### **Drug Formulation Market Dynamics**

Trends in Formulation Science  
Drug Discovery Automation  
Drug Development Productivity  
Preclinical Development Issues  
Value-added Contract Formulators  
Technology Market Drivers  
Formulation Strategies

### **Drug Formulation Technology Factors**

Drug Candidate Characterization  
Active Compound Stability  
Physicochemical Properties  
Pharmacokinetics  
Bioavailability  
Bioequivalence  
Drug Solubility  
ADME Analysis  
Routes of Administration  
Optimizing Drug Formulations

### **The Modern Formulation Toolbox**

Cyclodextrins  
Liposomes  
Nanoparticles  
Particle Engineering  
Supercritical Fluid Processing  
Polyethylene Glycol  
Emerging Approaches

### **Commercial Drug Formulation Technology Platform Assessments**

### **Implications on Drug Testing and Assurance**

Standards and Testing Criteria  
Testing Technology  
Compound Screening  
Compliance Issues  
Drug Test Systems  
Testing Supplier Profiles

### **Market Factors**

FDA Regulations  
Clinical Trials  
Formulation Partnerships  
Protein and Peptide-based Drugs  
Dosage Forms  
Drug Delivery Technology

### **Company Profiles**

Detailed Profiles of Market Sector Participants

---

## ***Market Data***

---

The study presents qualitative and quantitative data and information on key market measures and benchmarks:

- Drug Formulation Market Dynamics
- Technology Drivers
- Formulation Economic Factors
- Formulation Market Impact
- Therapeutic Demand Drivers
- Commercial Risk Factors
- User Segment Analysis
- Alliances and Strategies
- Participant Profiles
- Competitive Landscape
- Regulatory Factors
- Forecasts & Projections to 2011

## Methodology

---

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques

## Feature Summary

---

- Analyzes and evaluates drug formulation processes and technologies for improving the properties of insoluble, unstable, and/or poorly absorbed drug candidates
- Examines drug formulation technology issues and evolving market factors
- Provides detailed analysis and status of drug formulation technology platforms
- Forecasts the impact of formulation technology on drug development and manufacturing activities
- Profiles drug formulation technology market participants, their research activity, proprietary technology, and business strategies
- Evaluates the impact of economic, technology, and regulatory factors on drug formulation strategies and therapies

## Report Format and Availability

---

This report is available in hard copy or electronic format. A site license for a single physical location and a global license are also available. Publication is scheduled for February 2008, with availability on or before February 28<sup>th</sup>.

## About Greystone Associates

---

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

# Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

## Payment

We accept the following forms of payment:

**Company Check:** Please make checks payable to 'Greystone Associates'

**Credit Cards:** We accept MasterCard, Visa and American Express

**Wire Transfers:** See 'Wire Transfers' below for more information

### Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: Bank of New Hampshire  
300 Franklin Street  
Manchester, NH 03103  
(Call for Account Information)

Mailing Address: P.O. Box 1362  
Amherst, NH 03031

## Commercial Drug Formulation Technologies: Markets & Opportunities

Select	Format	Price (U.S. funds)	Total
<input type="checkbox"/>	Electronic	\$2,850.00	
<input type="checkbox"/>	Site License	\$4,500.00	
<input type="checkbox"/>	Global License	\$6,500.00	
<b>Total Payment (U.S. funds)</b>			

Method of Payment:  Company Check        Wire Transfer (International)

Card Number: \_\_\_\_\_ Name on Card \_\_\_\_\_

Expiration Date: \_\_\_\_\_ Signature \_\_\_\_\_

Billing Information	Shipping Information
	<input type="checkbox"/> Click here if same as Billing Information
Name:	Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: